Effectiveness of Bridging Therapy Corresponds to Improved Outcomes after Ciltacabtagene Autoleucel: Phase 3 CARTITUDE-4 Study of Patients with Relapsed, Lenalidomide-Refractory Multiple Myeloma

Transplantation and Cellular Therapy 2026

View at publisher
Authors: Binod Dhakal, Shinsuke Iida, M Hasib Sidiqi, Elena Zamagni, Sung‐Soo Yoon, Natalie S. Callander, Cyrille Touzeau, Quanlin Li, Ágnes Balogh, Ana Slaughter, Nina Benachour, Carolina Lonardi
+12 more Arnab Ghosh, Martin Vogel, Nikoletta K. Lendvai, Tamar Lengil, Mythili Koneru, Nitin Patel, Octavio Costa Filho, Vrinda Mahajan, Joaquin Martinez-Lopez, Kwee Yong, Katja Christina Weisel, Xavier P Leleu
DOI: 10.1016/j.jtct.2025.12.220
Cited by: 0

Fields of Study & Subjects

CAR-T cell therapy research Multiple Myeloma Research and Treatments Protein Degradation and Inhibitors

Publication details

Journal / source
Transplantation and Cellular Therapy
Volume
32
Issue
2
Pages
S161–S161
Publication date
1 February 2026
Language
EN